News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

New Study Confirms PayMedix Significantly Increases Net Cash Yield from Commercial Revenue for Hospitals and Healthcare Providers

HPS|PayMedix

MILWAUKEE, March 8, 2023 – At a time when 41% of U.S. adults have some form of healthcare debt, Health Payment Systems, Inc. (HPS) |PayMedix announced its PayMedix healthcare financing solution increases cash yield for healthcare organizations by as much as 9.5%, based on analysis reviewed by the Validation Institute. The savings encompass a healthcare organization’s total commercial allowed revenue, including both insurance and consumer out-of-pocket balances due. Providers do not re-negotiate pay or contracts or re-tool their existing revenue cycle processes. Instead, providers simply agree to participate with PayMedix and receive guaranteed payment. For a hospital with $200 million in commercial revenue, the PayMedix savings would yield $16 million in additional annual cash. Validation Institute is an independent, third-party organization dedicated to improving the quality and cost of healthcare. The review affirms that PayMedix’s ROI calculator produces a reasonable estimate of a healthcare provider’s savings using the PayMedix platform for commercially insured payments. By guaranteeing prompt full payment to healthcare providers and offering patients manageable repayment plans for all allowed in-network costs, regardless of their ability to pay, PayMedix reduces bad debt and increases net cash yield for providers. It eliminates financial risk for providers, as PayMedix assumes full responsibility for collecting patient balances. “Validation Institute’s review confirms the financial impact of PayMedix’s ability to reinvent and simplify the way healthcare payments are made,” said Tom Policelli, CEO of PayMedix. “Soaring out-of-pocket costs have become a $491 billion problem for the healthcare industry, with providers spending more to collect less. Providers no longer need to chase consumers after services are provided or demand payment before delivering care. By paying providers in full, we drastically reduce bad debt and collection costs. This allows providers to focus on what really matters—providing quality care to all patients.” In addition to increasing net cash yield, the PayMedix solution also increases patient access to needed healthcare services. Some patients today delay or avoid care due to cost concerns, and that can negatively impact overall healthcare outcomes and costs. PayMedix fixes that problem and thus increases health equity by guaranteeing payment to all providers for all participating consumers – regardless of their individual credit ratings. Measuring the additional revenue and cash that could be generated by this increase in patient access to services was outside the scope of the Validation Institute study. Any such gains would increase the value of PayMedix to health systems and provider organizations. The Validation Institute review simply certifies that the hard-dollar savings shown in the PayMedix ROI calculator reasonably estimate the savings to providers. PayMedix stands behind these estimates by making full, non-recourse payments to providers based on the model. Validation Institute’s review of PayMedix’s ROI calculator is also backed by the organization’s Credibility Guarantee. Validation Institute offers customers of the PayMedix solution up to $10,000 guarantee for its claims-based validation. This guarantee confirms that PayMedix will achieve what the validation language says it will achieve. “PayMedix is solving a critical financial challenge for healthcare providers by increasing their net cash yield and reducing their bad debt,” said Benny DiCecca, CEO of the Validation Institute. “We congratulate PayMedix for its pioneering work in changing the way people access, use, and pay for healthcare.” About Validation Institute Validation Institute is an independent, objective, third party organization on a mission to improve the quality and cost of healthcare. Based in Woburn, MA the organization is made up of a network of health benefits purchasers, health benefits advisors, and healthcare solution providers focused on delivering better health value and stronger outcomes than conventional healthcare. www.validationinstitute.com About PayMedix PayMedix, which began as the financing arm of Wisconsin-based HPS over a decade ago, is the only company solving the problem of high out-of-pocket costs for everyone: providers, patients, employers and TPAs. By guaranteeing payments to providers and credit for all patients, PayMedix is changing the way people access, use, and pay for healthcare. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. About HPS Health Payment Systems (HPS) is a privately held healthcare technology and services organization with solutions that reduce the cost and complexity of the healthcare payments process to benefit providers, employers, patients and TPAs. Headquartered in Milwaukee, Wisconsin, HPS has an independent network of 96 hospital facilities and 27,000 individual providers. Contact Details Brodeur Partners Kaitlynn Cooney +1 609-351-5944 kcooney@brodeur.com Company Website https://paymedix.com

March 08, 2023 09:00 AM Eastern Standard Time

Article thumbnail News Release

Roquefort Therapeutics establishes scientific advisory board

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Proactive's Thomas Warner after announcing the creation of a scientific advisory board. Reginald explains the rationale for the decision, before going to explain what each of the three-strong team will bring to Roquefort as it heads toward what he calls “key pre-clinical milestones”. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 08, 2023 08:22 AM Eastern Standard Time

Video
Article thumbnail News Release

Destiny Pharma "making real progress"

Destiny Pharma PLC

Destiny Pharma PLC (AIM:DEST) chief executive Neil Clark updates Proactive's Thomas Warner on the latest news from the clinical-stage biotech company. The update follows the announcement that Destiny has reached a collaboration and co-development agreement for its phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence. Clark says Destiny Pharma is "making real progess" and delivering on its strategy. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 08, 2023 08:19 AM Eastern Standard Time

Video
Article thumbnail News Release

Fine Hygienic Holding continues to roll out a progressive female-friendly approach with its latest Menopause and Fertility Treatment Policy

Fine Hygienic Holding

Fine Hygienic Holding (FHH), a world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has recently recommitted to its ongoing mission to make the workplace environment more inclusive and inviting for all its employees. The company has rolled out additional reforms in terms of its female-friendly policies to ensure everyone operates in a supportive environment. A step towards establishing positive change has been made, as the company is introducing the Fine Flourish Policy, which includes provisions for Menstrual, Menopause, and Fertility Treatment leaves, across all its locations. All female personnel - both full-time and probationary - are eligible to take advantage of the generous Fine Flourish policy. Employees are granted up to 12 days of leave annually in the event of any illness, symptoms, or complications related to menopause, menstruation, or fertility treatment. Moreover, flexible work arrangements can be made to ensure their comfort and convenience. All these provisions can be availed without a medical certificate and are granted separately from vacations or other leave policies. FHH is regarded as a pioneer in the region with its employee-friendly leave policies that offer time to recover both physically and emotionally. Kirsty Koen, FHH CHRO, said, “At Fine Hygienic Holding, we believe that a successful business must always prioritize its people. That’s why one of our core values has always been - if we take care of our people, the business will take care of itself. We are constantly exploring new methods and practices that will help ensure our employees are supported in every aspect, especially during times when they need it the most. Every policy we announce is tailored to embody our values and to provide support, and we will continue to be dedicated to looking after the wellbeing of our people and pave the way for woman employment across the Middle East.” Fine Hygienic Holding has already set the bar high in this field when it previously introduced a series of progressive leaves on top of which is its menstrual leave, which the company launched more than 10 years ago. For mothers to be, FHH provides up to 16 weeks of fully paid maternity leave, which is far more than the recommendations of the International Labour Organization. Furthermore, the company has amended its parental leave policy, allowing three weeks of paid paternity leave, and has also set a benchmark in global and regional companies by introducing a compassionate leave wherein a female employee or the spouse of an employee is granted a paid leave in cases of miscarriages or stillbirths. Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director +971 54 531 5575 Rkawalit@finehh.com Company Website https://www.finehh.com/

March 08, 2023 01:40 AM Eastern Standard Time

Article thumbnail News Release

1606 Corp lands key acquisition with 51% stake in CBD supplier Brio Nutrition

1606 Corp.

1606 Corp CEO Greg Lambrecht joins Proactive's Natalie Stoberman with details of the company's purchase of a 51% stake in CBD supplier Brio Nutrition. Lambrecht said the acquisition includes the addition of over 45 products to the 1606 lineup, access to all Brio customer data and distribution channels for cross-marketing the 1606 line of products, as well as the opportunity to use 1606 to expand Brio's CBD development and distribution. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

March 07, 2023 01:02 PM Eastern Standard Time

Video
Article thumbnail News Release

Mindset Pharma and PharmAla partnership makes first medical grade psilocybin sale in Australia

Mindset Pharma Inc

Mindset Pharma CEO James Lanthier and PharmAla CEO Nick Kadysh join Proactive's Natalie Stoberman to announce their first sale of pharmaceutical grade psilocybin into the Australian market. Lanthier and Kadysh said the psilocybin is being purchased by Reset Mind Sciences Limited, a Western Australian based company focused on psychedelic medicines, and a subsidiary of ASX-listed Little Green Pharma. The CEOs added that regulatory developments in Australia have opened the door to more opportunities for their partnership that combines Mindset's novel synthesis processes and PharmAla's sales infrastructure. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

March 07, 2023 12:06 PM Eastern Standard Time

Video
Article thumbnail News Release

The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury

Unicycive Therapeutics, Inc.

By Julian Richard, Benzinga Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver quality of life due to kidney failure. Its candidate UNI-494 is currently in development for treating acute kidney injury (AKI). Acute kidney injury (AKI) is a serious, life-threatening condition caused by an acute loss of kidney function. There are several causes of AKI, including heart failure and liver disease, blockage to the kidney and reduced blood flow, and drugs or toxic substances. Recent research has highlighted the role that mitochondrial dysfunction plays in AKI pathogenesis. Mitochondria are organelles (specialized structures within cells that perform specific functions) that produce energy for cell functions and regulate many other biological processes, such as cell death. When mitochondria become dysfunctional due to illness or trauma, it can lead to various diseases, including AKI. Treatment for AKI currently focuses on supportive care measures such as administering fluids and electrolytes to stabilize the patient’s blood pressure and dialysis treatment to remove waste from the body. While these treatments are effective in treating the symptoms of AKI, they fail to address the underlying cause of this medical condition and thus do not affect the progression of the disease. Symptoms of AKI include decreased frequency of urination and swelling in the legs and may lead to chronic kidney disease if not treated. Unfortunately, treatment options for mitochondrial dysfunction are limited. While several promising treatments can restore mitochondrial function, such as using antioxidants and other compounds to reduce oxidative stress, these treatments have yet to be successfully implemented on a large scale. This unmet medical need has left many patients with few treatment options. UNI-494 is a promising compound seeking to address this unmet clinical need. It is a patented pro-drug (a biologically inactive compound that can be metabolized in the body to produce an active drug) of nicorandil, which has been shown in preclinical models to improve mitochondrial function. Data for UNI-494 from three pre-clinical studies will be presented at the National Kidney Foundation’s (NFK) upcoming Spring Clinical Meetings in April 2023. “We are delighted to be presenting this bolus of data in support of UNI-494 as a potential treatment advance for acute kidney injury” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive Therapeutics. Visit https://unicycive.com for more information on the company and its product candidates. This article was originally published on Benzinga here. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

March 07, 2023 09:00 AM Eastern Standard Time

Article thumbnail News Release

Keep Underestimating Michigan: This Midwest Powerhouse is Just Hitting its Stride

Cannabis Attorneys of Michigan

By Denise Pollicella, Esq. It is no secret that Michigan cannabis businesses have had a rough time of it lately. The market consolidation that took three to five years in other maturing legal cannabis states compressed into the span of roughly 18 months in Michigan in which the wholesale price of marijuana cratered by an astounding 90%. This is in a state that most MSOs had already passed on, primarily due to the unlimited state license structure. Over-leveraged and cash-poor companies with limited to no options for traditional financing found no help from the private equity market, which appears to have pulled up stakes for the younger and more fertile East Coast. But those quick to write Michigan off are not paying close enough attention. Take, for example, the wholesale price of marijuana. According to Leaflink’s Wholesale Cannabis Pricing Guide, Michigan had a 3.2 score in 2020 (1 being the highest on a 1 – 10 scale). At the time, Michigan had the third highest flower prices in the country, and the second highest concentrate prices in the country, while the more mature states in the West and Southwest had the lowest. But in Leaflink’s 2022 Guide, even though Michigan’s score fell to 4.8, it was still well above the more mature West and Southwest markets and continues to hold the spot for the third-highest flower prices in the country. It is in the edibles and cartridges that the state has seen the steepest declines. Still, after the expected brief Croptober dip, Michigan has seen its prices level off and even tick up slightly. The sigh of relief from growers across the state has been almost audible. Demand in the legal market is also increasing, thanks to Detroit, Port Huron and Traverse City all finally permitting recreational adult use retailers after years of messy litigation. Twenty-four are already online in Detroit, with a second application period due to open in March, which will likely bring at least another two dozen online in short order, all in the state’s most populous city, and all before the start of baseball season and a host of arts and cultural events that bring fans and tourists to Michigan in the Summer. A completely non-scientific poll of my own licensed cannabis retailers in Detroit shows an increase of roughly $150,000 monthly in sales and climbing from the addition of recreational adult use licensing. While the majority of the State’s most populous cities have already welcomed not only the licensed cannabis industry as a whole but recreational adult use retailers, the number of retailers will likely continue to climb as the more than 1,300 Michigan municipalities who opted out of the recreational adult use market watch the state write nearly $61,000,000 in checks to the 129 municipalities who did, up nearly $17,000,000 from 2021’s distribution. At $51,800 per retailer and microbusiness license, smaller cities are starting to run out of reasons to “just say no”. And let’s not forget about Michigan’s border towns, now the most sought-after locations in the state: in the South, bordering Indiana and Ohio, and in the North, bordering Wisconsin. A mere 45-minute drive from Green Bay on the East and a 90-minute drive from Minneapolis on the West, Michigan’s Upper Peninsula is booming. Whether cannabis is federally legalized or not, Michigan is situated, both in infrastructure and location, to dominate the Midwest for the next ten years. This expected growth in continued revenue, taxes, and demand is good news for the Michigan licensed cannabis industry, which, by all accounts, has not met the projected demand of the state’s reported cannabis-consuming population. So while the consolidation happened earlier than anyone expected, and we will continue to argue about why, it was, in the end, inevitable and necessary, and the businesses that survived came out all the stronger for it. As a state, Michigan certainly still has its challenges, and for our legal cannabis industry’s age, our laws and policies very often do not reflect maturity. We seem determined to continue to disregard a $2 billion industry that has created over 30,000 primary full-time, living wage jobs, and is rapidly becoming the primary revenue generator for many of Michigan’s communities, big and small. We have a lot of work to do, and not all of it will be painless. The MSOs can continue to pass Michigan on the way to Massachusetts and New Jersey. We don’t mind. That was never Michigan’s plan. If you have been to even one planning commission meeting in rural Michigan, you already know that Michigan prefers its businesses to be locally owned and operated. We are an agricultural, manufacturing state that has always thrived on free market competition and local economic development, and Michigan’s cannabis industry fits in nicely. Denise Pollicella is the Founder and Managing Partner of Cannabis Attorneys of Michigan and a business attorney in her 27 th year of practice. See her bio at cannabisattorneysofmichigan.com This article was originally published on Benzinga here. Cannabis Attorneys of Michigan are experts in licensing and representation for Michigan’s cannabis industry since 2009 Contact Details Tiffinay Burgess Tiffinay.burgess@pollicella.net

March 06, 2023 12:00 PM Eastern Standard Time

Article thumbnail News Release

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?

Coya Therapeutics Inc.

By David Willey, Benzinga Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field. When the father of company CEO and founder Howard Berman was diagnosed with dementia, Berman became inspired to turn his expertise in neuroscience towards developing a treatment that could help his father and others like him. Now the company has conducted trials that show the promise of a new therapy to slow or stop neurodegenerative diseases like Parkinsons, Alzehimers, and Amyotrophic Lateral Sclerosis (ALS), as well as other autoimmune and metabolic diseases. Cell and gene therapy (CGT) is a growing biomed market. It is currently worth over $18 billion and was forecasted to grow at a compound annual growth rate (CAGR) of 22.41% by Precedence Research, bringing its value to over $93 billion by 2030. Regulatory T cell (Treg) therapy is a developing field in the cell therapy market. It has been inspired by the successes of Chimeric antigen receptor (CAR)-T cell therapies for treating cancer. CAR-T treatments, which engineer the immune system to respond to the cancerous cells, have seen high complete remission rates in cancer patients suffering from cancers like B-cell acute lymphoblastic leukemia (B-ALL). Treg-based therapies look to apply the innovations of CAR-T therapy to other diseases. It's an exciting field, with around $3 billion raised by investors over the past decade. More than 180 trials for Treg therapy have been registered in the past twenty years, however the majority of these trials are still pre-clinical. While many companies involved in Treg-based therapy remain in the pre-clinical stage, one is already bringing data to the table. Coya Therapeutics is advancing multiple Treg-based therapy modalities and is one of the most clinically advanced companies in the Treg field. Coya Is Tackling Inflammation At Its Source Many neurodegenerative diseases, including ALS and Parkinson's Disease, are often driven by widespread inflammation, resulting from a malfunction of Treg cells. Coya Therapeutics is investigating Treg’s potential for reducing inflammation by modifying the Treg cell to make it functional again and down-regulate the cytokine inflammation. The company believes that restoring Treg cells’ functionality could either slow or stop the spread of these diseases. Unlike some others in the market, Coya has been able to bring its therapies to the clinic. With its Coya-101 therapy, it has validated this approach for cell therapy, with two trials that either slowed or stopped the disease’s progression. With its Coya 302 therapy, it is also looking to add biologics to its portfolio. In two proof of concept studies, the company has identified two biologics which treat Alzheimers and ALS, and biomarkers indicate patients seeing some recovery for the disease. Also biologic treatments, which are derived from living organisms as opposed to synthetic chemicals, have the advantage of being both cheaper and more scalable than traditional treatments. Biologics can be developed as “off the shelf” therapies, as opposed to the more time-consuming autologous treatments that are specific to each patient. Other companies working in the TREG space include Sonoma Biotherapeutics, which has received investment from the venture arm of Eli Lilly and Company (NYSE: LLY), GentiBio, which has seen investment from the venture arm of Novartis (NYSE: NVS), and Abata Therapeutics. Treg-based therapies are a unique way to target inflammation and potentially reverse the spread of the disease at the cellular level. Currently there are only two FDA-approved drugs on the market to treat ALS and Frontotemporal dementia (FTD), and they don’t seem to halt the disease. While studies have sought to reduce inflammation in ALS patients using drugs like cyclooxygenase–2, or through experimental therapies that use intracerebral and intrathecal delivery, these approaches are either too invasive or don’t appear to reduce inflammation. Coya believes its novel cell therapy could see positive results, just as CAR-T treatment saw cancer remission rates without the negative side effects of treatments like chemotherapy. Want to learn more about Coya Therapeutics and its Treg therapies? Visit its website. This article was originally published on Benzinga here. About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

March 06, 2023 09:00 AM Eastern Standard Time

1 ... 130131132133134 ... 284